92 research outputs found
Should the host reaction to anisakiasis influence the treatment? Different clinical presentations in two cases
Gastrointestinal anisakiasis is a parasitic infection occurring in people that consume raw or inadequately cooked fish or squid. It is frequently characterized by severe epigastric pain, nausea and vom iting caused by the penetration of the larvae into the gastric wall. Acute gastric anisakiasis with severe chest discomfort is rarely report ed in Italy. On the other hand, gastro-allergic anisakiasis with rash, urticaria and isolated angioedema or anaphylaxis is a clinical entity that has been described only recently. Also, if patients usually develop symptoms within 12 hours after raw seafood ingestion, not always endoscopic exploration can promptly identify the Anisakis larvae. Moreover, some authors consider the prevailing allergic reaction as a natural and effective defense against the parasitic attack. We report two cases of peculiar manifestations of anisakiasis in both acute and chronic forms (severe chest discomfort and anaphylactoid reaction)
Impact of time to surgery after neoadjuvant chemotherapy in patients with operable breast cancer.
Background: Some studies of adjuvant chemotherapy (CT) suggested that a shorter interval before the start of therapies may
improve survival outcomes in many groups of patients. Time to surgery (TTS) after neoadjuvant CT and survival outcomes have
not been established yet. The aim of this study is to evaluate the impact of TTS after neoadjuvant CT in terms of Overall Survival
(OS) and Disease Free Survival (DFS).
Patients and Methods: A retrospective analysis was conducted in 295 patients receiving neoadjuvant CT for stage I-IIIc breast
cancer between 1991 and 2013. 56 pts underwent surgery within 21 days (group A) from last CT cycle, 148 pts within 22-35 days
(group B) and 91 pts after 36 days (group C). The majority were infiltrating ductal carcinoma, stage IIA (37.6%) and IIB
(33.9%), with nodal involvement in 51.6% of the cases. LumA 18.3%, LumB/HER2- 28.2%, LumB/Her2+ 20.7%, HER2+ 9.8%,
TNBC 21%. All patients were treated with neoadjuvant CT: 70.5% with anthra-taxanes based regimen, 18% with anthra- alone,
10.9% with taxanes alone, 0.3% with CMF; plus Trastuzumab in 70% of HER2+ diseases.
Results: After a median follow up of 4.6 years, it was observed that patients in group A showed a significant better OS than
group B (HR 4.22; 95% CI, 1.27 \u2013 14.00, p=0.018) and group C (HR 3.61; 95% CI, 1.01 \u2013 12.86, p=0.048). Moreover group A
showed a significant better DFS than group B (HR 3.41; 95% CI 1.34 to 8.65, p=0.010) and group C (HR 3.77; 95% CI 1.42 to
9.95, p=0.007).
No correlations with OS were found in pts who achieved pCR (20.7%); pCR was predictive of better 5- and 10-years DFS
independently from TTS (95.4% in the pCR-group vs 75.4% of non-pCR group, HR 0.16; 95% CI 0.04 to 0.66, p=0.011). TTS
may influence DFS in non-pCR group: indeed 5-years DFS is 97.3% in group A, 72.7% in group B (HR 2.89; 95% CI 1.14 to
7.36, p=0.026), and 68.5% in group C (HR 3.44; 95% CI 1.3 to 9.1, p=0.013). No significant correlations with regard of stage at
diagnosis or molecular subtypes were found.
Conclusions: These results suggest that TTS after primary CT may influence patients' survival, regardless of stage at diagnosis
and tumor subtype, so that a shorter interval between that last cycle of neoadjuvant chemotherapy and breast surgery should be
addressed whenever possible
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases .
Background
Bone is one of the most frequent sites of metastasis in patients with advanced cancer. Nearly all patients with myeloma, 65–75%
of patients with prostate or breast cancer, and 30–40% of patients with lung cancer or other solid tumors, eventually develop bone
metastases. Bisphosphonates (BP), particularly zoledronic acid and denosumab, were demonstrated to effectively reduce skeletal
complications in patients with bone metastases. However, bisphosphonate-related osteonecrosis of the jaw (BRONJ) can occur
spontaneously, favored by dental extraction, dental implant surgery, or denture wearing. The purpose of this study was to
underline the role of dental prevention as an effective tool to reduce the risk of BRONJ.
Material and methods
BRONJ was identified with the standardized query “osteonecrosis” among all data from patients treated at Modena Cancer
Center from 2005 to 2016. For each case, demographic and medical information were analyzed, as well as data about notification
(year of occurrence, outcome), type and duration of BP exposure, and associated risk factors (dento-alveolar surgery,
chemotherapy, antiangiogenics). Data were differently analyzed taking into account the implementation of a Dental Prevention
Service in patients who are candidates for BP therapy.Results
Among 1663 patients treated with BP, 63 cases of BRONJ were identified (3.8%). 44 female and 19 men with a median age of 69
years (range 47-90 years), have been treated with BP for bone metastases from breast cancer (54%), hematologic malignancy
(21%), prostate cancer (13%), renal cancer (5%), lung cancer (2%) and other tumors (5%). 15 maxillae and 48 mandibles were
involved. The trigger event was a dental extraction in 29% of the cases, being spontaneously the other 71%. The median time to
BRONJ was 28 months (range 1-89.1 months) from the first dose of BP, and 25 was the mean number of BP doses administered
before BRONJ. Overall, a preliminary odontoiatric evaluation was performed in only 14 cases (22%). All but one of these
dentistry opinions were obtained after 2010 when the Dental Prevention Service was created, which is a drop out of the risk of
BRONJ from 4.1 to 1.9%.
Conclusions.
Prevention of the BRONJ is critical in in bone metastatic patients. The incidence of BRONJ over time can drop to 1.9% when
primary and secondary prevention measures are implemented in routine clinical practice
Dissecting Immunotherapy Strategies for Small Cell Lung Cancer: Antibodies, Ionizing Radiation and CAR-T
Small cell lung cancer (SCLC) is a highly aggressive malignancy that accounts for about 14% of all lung cancers. Platinum-based chemotherapy has been the only available treatment for a long time, until the introduction of immune checkpoint inhibitors (ICIs) recently changed first-line standard of care and shed light on the pivotal role of the immune system. Despite improved survival in a subset of patients, a lot of them still do not benefit from first-line chemo-immunotherapy, and several studies are investigating whether different combination strategies (with both systemic and local treatments, such as radiotherapy) may improve patient outcomes. Moreover, research of biomarkers that may be used to predict patients’ outcomes is ongoing. In addition to ICIs, immunotherapy offers other different strategies, including naked monoclonal antibodies targeting tumor associated antigens, conjugated antibody, bispecific antibodies and cellular therapies. In this review, we summarize the main evidence available about the use of immunotherapy in SCLC, the rationale behind combination strategies and the studies that are currently ongoing in this setting, in order to give the reader a clear and complete view of this rapidly expanding topic
Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study
Epidermal growth factor receptor T790M detection using liquid biopsy was evaluated in a real-life setting in 120 advanced non–small-cell lung cancer patients whose disease had progressed during first- or second-generation tyrosine kinase inhibitors. The T790M detection rate was 25.8% using liquid biopsy and 49.2% after tissue rebiopsy. Liquid biopsies performed before disease progression according to Response Evaluation Criteria In Solid Tumors were all negative for T790M and T790M positivity was higher in cases of extrathoracic metastatic sites
Recommended from our members
Psychometric evaluation of the Italian Revised Exercise Addiction Inventory (EAI-R) among Italian speaking exercisers: confirmatory factor analysis
Background: The Exercise Addiction Inventory (EAI) is a valid and reliable instrument and has been used in numerous contexts and research studies. The EAI was recently revised (EAI-R), but the psychometric properties of the EAI-R have yet to be examined in an Italian context. Therefore, the present study aimed to validate the EAI-R among Italian-speaking exercisers.
Methods: The sample comprised 200 Italian-speaking exercisers (62% females, 38% male; mean age = 35 years, SD±11.42), who completed a survey including the EAI-R, Depression Anxiety and Stress Scale-21 (DASS-21), Rosenberg's Self-Esteem Scale (RSES), and Exercise Dependence Scale-Revised (EDS-R).
Results: Confirmatory factor analysis (CFA) showed the EAI-R had good psychometric characteristics (Cronbach's α = 0.90) and confirmed the scale's unidimensional properties. Scores on the EAI-R were positively correlated with EDS-R scores, the number of weekly hours of exercise, and DASS-21 scores. Conversely, EAI-R scores were negatively correlated with the RSES scores and age.
Conclusion: The EAI-R is a psychometrically reliable and valid measure for assessing the risk of exercise addiction among Italian adults. The study expands the literature on exercise addiction and demonstrates important associational factors in the Italian context
Recommended from our members
Validation and psychometric evaluation of the Italian version of the Bergen–Yale Sex Addiction Scale
Excessive problematic sexual behavior in the form of compulsive sexual behavior disorder (CSBD), hypersexuality (HS), and sex addiction has gained increasing credibility in recent years and has led to the development of various psychometric instruments to assess such behavior. However, there is still considerable controversy over the operational definition of such concepts and whether they can be used interchangeably to describe the behavior. One recently developed tool is the Bergen–Yale Sex Addiction Scale (BYSAS) based on the “components model of addiction.” The present study validated the Italian version of the BYSAS. The BYSAS was administered to a large Italian-speaking sample of Italian adults [N = 1230, aged 18 to 67 years] along with psychometric instruments assessing the “Big Five” personality traits, self-esteem, depression, and two other measures of addictive sexual behavior (i.e., PATHOS and Shorter PROMIS Questionnaire–Sex Subscale). Confirmatory factorial analysis supported a one-factor solution. Furthermore, the scale had good internal consistency (Cronbach’s α = 0.787). The BYSAS was positively associated with extroversion, openness to experience, depression, and problematic sexual behavior, and negatively associated with self-esteem, conscientiousness, emotional stability, agreeableness, and age. Based on the findings, the BYSAS is a brief, psychometrically reliable and valid measure for assessing sex addiction among Italian adults
Recommended from our members
The LRRK2 signalling system
The LRRK2 gene is a major contributor to genetic risk for Parkinson's disease and understanding the biology of the leucine-rich repeat kinase 2 (LRRK2, the protein product of this gene) is an important goal in Parkinson's research. LRRK2 is a multi-domain, multi-activity enzyme and has been implicated in a wide range of signalling events within the cell. Because of the complexities of the signal transduction pathways in which LRRK2 is involved, it has been challenging to generate a clear idea as to how mutations and disease associated variants in this gene are altered in disease. Understanding the events in which LRRK2 is involved at a systems level is therefore critical to fully understand the biology and pathobiology of this protein and is the subject of this review
- …